secwatch.observer — SEC 8-K summary
======================================

Issuer:     Peak Bio, Inc. (—)
CIK:        0001834645
Form:       8-K
Filed at:   2024-09-03T23:59:59+00:00
Accession:  0000950170-24-102801
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Interim CEO Stephen LaMond resigns; Executive Chairman Hoyoung Huh assumes CEO duties
--------------------------------------------------------------------------------

- Stephen LaMond resigned as Interim CEO and COO, effective Aug 31, 2024; will serve as consultant.
- Separation agreement: $524,300 consulting fee paid in 24 monthly installments starting Sept 1, 2024.
- LaMond receives option for 875,000 shares at $0.80 vesting in three tranches through Dec 31, 2025.
- Board appoints Executive Chairman Hoyoung Huh to assume CEO responsibilities effective Aug 31, 2024.
- Consulting fee includes $24,300 for 6 months of health coverage; COBRA for 18 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1834645/000095017024102801/0000950170-24-102801-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1834645/000095017024102801/pkbo-20240827.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-102801

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer